+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 40Years
FEMALE
ID06147388

Study of Regression in Severe Cervical Precancerous Lesions CIN 2 and CIN 3 and Related Risk Factors in Women Aged 18 to 40

Led by General University Hospital, Prague · Updated on 2026-02-25

300

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to understand how often severe cervical precancerous lesions CIN 2 and CIN 3 naturally get better without surgery. It also compares patients treated with close monitoring and those who had surgical removal conization by looking at HPV test results and cell changes. The study will identify factors that predict lesion improvement and develop a model to estimate the chances of regression. The study follows women aged 18 to 40 who have confirmed CIN 2 or CIN 3 lesions visible during colposcopy. Participants undergo colposcopic exams every four months to monitor lesion changes. If the lesion worsens, surgery is recommended if persistent, patients can choose continued observation or surgery if the lesion improves, a biopsy is taken to confirm healing. HPV status and cell changes are also monitored, along with other factors like age and HPV type. Participants will have regular colposcopic evaluations and tests over three years to track lesion regression and changes in HPV and cytology results. The main outcome is the rate of lesion regression based on tissue samples. Researchers will also assess HPV clearance and cell normalization rates, considering factors that might influence outcomes. Safety and disease progression are monitored throughout, with data used to build a predictive model for lesion regression.

CONDITIONS

Brief Title

Regression of Cervical Precancerous Lesions and Associated Risk Factors

Research Team

L

Lukas Dostalek

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here